BIOKID-PG
| Patologia: | Malattie infiammatorie intestinali pediatriche |
| Area Tematica: | Medicina personalizzata |
| Data di Inizio Progetto: | 01/05/2026 |
| Data di Fine Progetto: | 01/05/2029 |
| Finanziamento: | € 500.000,00 |
| Partenariato | IRCCS Policlinico Ca’ Granda (Milano) Fundación para la Investigación Biomédica (Spagna) Klinikum der Ludwig-Maximilians-Universität München – Dr. von Hauner Children’s Hospital (Germania) The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition (Israele) European Federation of Crohn’s & Ulcerative Colitis Associations Secretariat (Belgio) EDGENEERING Lda. – Innovation Department (EDGE) (Portogallo) |
BIOKID-PGx aims to revolutionize pediatric inflammatory bowel disease (pIBD) treatment by pioneering personalized medicine through an innovative, multi-omics-based risk score predicting anti-TNF therapy failure. This ambitious project leverages multi-omics data and cutting-edge machine learning to identify and validate key biomarkers associated with anti-TNF drug response.
Initially, existing omics data from consortium partners will be integrated to identify and validate biomarkers of response to anti-TNF drugs. Previous results unveiled at least 391 single nucleotide variants and the expression of 109 genes as potential biomarkers based on whole exome sequencing and transcriptomic data. We expect that integrating multi-omics data into a unified analysis will yield more robust markers. These will then be validated in new patient cohorts, using partners’ existing collections and a collaboration with the PORTO IBD biobank.
Following validation, a machine learning-generated risk score will be developed using a minimal set of omics biomarkers, personalized by sex, IBD type, and specific anti -TNF treatment. This risk score will be prospectively validated in a cohort of children with IBD recruited by the PORTO IBD biobank. We expect >90% accuracy in predicting anti-TNF treatment failure after one year.
Guidelines for using and interpreting this risk score will be created for rapid and safe clinical implementation. Patient involvement is central through EFCCA. A digital platform for the risk score will be developed, and a clinical trial protocol designed, fostering collaboration between patients, clinicians, and industry. Key performance indicators include software development, clinical trial protocol establishment, and patient and industry stakeholder meetings.
Our collaborative ecosystem ensures the project’s outcomes are relevant, impactful, and translatable to real-world clinical settings, ultimately improving the lives of children with IBD.